NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that it has completed the acquisition of 100% of Zorronet...
NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc . (NYSE American: PHGE) today announced that it has entered into an option agreement to acquire control of DFSL , a developer of proprietary...
NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board. Dr. Levi will support...
NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the Company received a notice from the staff of NYSE...
NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance...
CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities
Seasoned financial leaders join BiomX to support strategic execution and advancement of the company
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in...